NEW YORK – The double-digit reduction in the corporate tax rate and the repatriation provision included in the tax code changes signed into law late last year were hailed as boons for the U.S. biopharma sector, with many pundits predicting that 2018 will finally bring a much-anticipated M&A frenzy.
NEW YORK – Coming off a slower-than-usual year in biopharma M&A activity – due largely to drug pricing pressures and regulatory uncertainty, coupled with a robust financing environment – many industry observers have tagged 2018 to be a busy year in acquisitions.
Biopharma’s financing frenzy continued Thursday, with eight firms pricing public offerings – six follow-ons and two IPOs – to raise a total of about $760.7 million before overallotments.
SAN FRANCISCO – A shifting regulatory climate and an increasing push for innovation combined with a staggering amount of capital is expected to significantly increase the rate of cross-border dealmaking between China firms and U.S.-based and multinational companies, experts predicted during the Chinese American Biopharmaceutical Society meeting last week.
SAN FRANCISCO – A shifting regulatory climate and an increasing push for innovation combined with a staggering amount of capital is expected to significantly increase the rate of cross-border dealmaking between China firms and U.S.-based and multinational companies, experts predicted during the Chinese American Biopharmaceutical Society meeting Wednesday.
SAN FRANCISCO – While the past decade has seen the rise of money from family offices into direct investments, a lack of knowledge and expertise has kept many of those funds on the sidelines when it comes to the health care sector. But the ones willing to take risks on innovative prospects could help young firms bridge the gap between an idea and a much-needed inflection point.
SAN FRANCISCO – If 2017 marked a year of big wins for scientific innovation with the FDA approvals of the first three gene therapies – Novartis AG's Kymriah (tisagenlecleucel) CAR T immunotherapy for B-cell acute lymphoblastic leukemia, Kite Pharma Inc.-developed CAR T Yescarta (axicabtagene ciloleucel) for certain types of non-Hodgkin lymphoma and more "traditional" gene therapy Luxturna (voretigene neparvovec-rzyl) from Spark Therapeutics Inc. to treat RPE65 mutation-associated retinal dystrophy – then 2018 might be the year when the innovative capabilities on the payer side are put to the test.
ATLANTA – With last month's early FDA nod for bispecific antibody Hemlibra (emicizumab) – more than three months ahead of its PDUFA date – and a rapidly advancing gene therapy candidate, the treatment landscape for hemophilia A is poised for a dramatic change.
Shares of Acorda Therapeutics Inc. (NASDAQ:ACOR) took a hit Wednesday, falling $11.20 to close at $17, on reports of potentially treatment-related adverse events in its tozadenant program for Parkinson's disease. While reports of agranulocytosis that led to cases of sepsis and death prompted analysts to drop the drug from their models, the Ardsley, N.Y.-based firm has no plans at this time to discontinue work on the phase III oral adenosine A2a receptor antagonist it acquired in last year's buyout of Biotie Therapies Oyj.
